898 related articles for article (PubMed ID: 25677920)
1. Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial.
Shehata M; Hamza M
Cardiovasc Ther; 2015 Apr; 33(2):35-41. PubMed ID: 25677920
[TBL] [Abstract][Full Text] [Related]
2. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
[TBL] [Abstract][Full Text] [Related]
3. High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial.
Billings FT; Hendricks PA; Schildcrout JS; Shi Y; Petracek MR; Byrne JG; Brown NJ
JAMA; 2016 Mar; 315(9):877-88. PubMed ID: 26906014
[TBL] [Abstract][Full Text] [Related]
4. Prevention of contrast-induced nephropathy with single bolus erythropoietin in patients with diabetic kidney disease: A randomized controlled trial.
Shema-Didi L; Kristal B; Eizenberg S; Marzuq N; Sussan M; Feldman-Idov Y; Ofir P; Atar S
Nephrology (Carlton); 2016 Apr; 21(4):295-300. PubMed ID: 26370061
[TBL] [Abstract][Full Text] [Related]
5. Elevated homocysteine and the risk of contrast-induced nephropathy: a cohort study.
Barbieri L; Verdoia M; Schaffer A; Niccoli G; Perrone-Filardi P; Bellomo G; Marino P; Suryapranata H; Luca GD
Angiology; 2015 Apr; 66(4):333-8. PubMed ID: 24830422
[TBL] [Abstract][Full Text] [Related]
6. Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction.
Toso A; Leoncini M; Maioli M; Gallopin M; Tedeschi D; Amato M; Bellandi F
J Cardiovasc Med (Hagerstown); 2011 May; 12(5):318-21. PubMed ID: 21045713
[TBL] [Abstract][Full Text] [Related]
7. Statins and contrast-induced acute kidney injury with coronary angiography.
Gandhi S; Mosleh W; Abdel-Qadir H; Farkouh ME
Am J Med; 2014 Oct; 127(10):987-1000. PubMed ID: 24852935
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial.
Iranirad L; Hejazi SF; Sadeghi MS; Jang SA
Cardiol J; 2017; 24(5):502-507. PubMed ID: 28281738
[TBL] [Abstract][Full Text] [Related]
9. High Loading Dose of Atorvastatin for the Prevention of Serum Creatinine and Cystatin C-Based Contrast-Induced Nephropathy Following Percutaneous Coronary Intervention.
Fu N; Liang M; Yang S
Angiology; 2018 Sep; 69(8):692-699. PubMed ID: 29343076
[TBL] [Abstract][Full Text] [Related]
10. Effect of a Contrast Modulation System on Contrast Media Use and the Rate of Acute Kidney Injury After Coronary Angiography.
Mehran R; Faggioni M; Chandrasekhar J; Angiolillo DJ; Bertolet B; Jobe RL; Al-Joundi B; Brar S; Dangas G; Batchelor W; Prasad A; Gurm HS; Tumlin J; Stone GW
JACC Cardiovasc Interv; 2018 Aug; 11(16):1601-1610. PubMed ID: 30139467
[TBL] [Abstract][Full Text] [Related]
11. Impact of trimetazidine on incidence of myocardial injury and contrast-induced nephropathy in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention.
Shehata M
Am J Cardiol; 2014 Aug; 114(3):389-94. PubMed ID: 24927970
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumour necrosis factor receptors 1 and 2 predict contrast-induced nephropathy and progressive renal dysfunction: a prospective cohort study.
An JN; Yoo KD; Hwang JH; Kim HL; Kim SH; Yang SH; Kim JH; Kim DK; Oh YK; Kim YS; Lim CS; Lee JP
Nephrology (Carlton); 2015 Aug; 20(8):552-9. PubMed ID: 25783484
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of short-term high versus low doses of atorvastatin preventing contrast-induced acute kidney injury in patients undergoing coronary angiography/percutaneous coronary intervention.
Wu H; Li D; Fang M; Han H; Wang H
J Clin Pharmacol; 2015 Feb; 55(2):123-31. PubMed ID: 25310898
[TBL] [Abstract][Full Text] [Related]
14. Frequency and risk factors of contrast-induced nephropathy after cardiac catheterization in type II diabetic patients: a study among Egyptian patients.
Sany D; Refaat H; Elshahawy Y; Mohab A; Ezzat H
Ren Fail; 2014 Mar; 36(2):191-7. PubMed ID: 24138570
[TBL] [Abstract][Full Text] [Related]
15. Continuous intravenous infusion of nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against contrast-induced nephropathy in patients with poor renal function.
Nawa T; Nishigaki K; Kinomura Y; Tanaka T; Yamada Y; Kawasaki M; Minatoguchi S
Int J Cardiol; 2015 Sep; 195():228-34. PubMed ID: 26048382
[TBL] [Abstract][Full Text] [Related]
16. High-dose atorvastatin for preventing contrast-induced nephropathy in primary percutaneous coronary intervention.
Jo SH; Hahn JY; Lee SY; Kim HJ; Song YB; Choi JH; Choi SH; Lee SH; Gwon HC
J Cardiovasc Med (Hagerstown); 2015 Mar; 16(3):213-9. PubMed ID: 25032713
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease.
Toso A; Maioli M; Leoncini M; Gallopin M; Tedeschi D; Micheletti C; Manzone C; Amato M; Bellandi F
Am J Cardiol; 2010 Feb; 105(3):288-92. PubMed ID: 20102936
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial).
Kaya A; Kurt M; Tanboğa IH; Işik T; Ekinci M; Aksakal E; Kaya Y; Topçu S; Sevimli S
Acta Cardiol; 2013 Oct; 68(5):489-94. PubMed ID: 24283110
[TBL] [Abstract][Full Text] [Related]
19. Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention).
Toso A; Leoncini M; Maioli M; Tropeano F; Di Vincenzo E; Villani S; Bellandi F
JACC Cardiovasc Interv; 2014 Dec; 7(12):1421-9. PubMed ID: 25523533
[TBL] [Abstract][Full Text] [Related]
20. Short-Term High-Dose Vitamin E to Prevent Contrast Medium-Induced Acute Kidney Injury in Patients With Chronic Kidney Disease Undergoing Elective Coronary Angiography: A Randomized Placebo-Controlled Trial.
Rezaei Y; Khademvatani K; Rahimi B; Khoshfetrat M; Arjmand N; Seyyed-Mohammadzad MH
J Am Heart Assoc; 2016 Mar; 5(3):e002919. PubMed ID: 27068631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
